San Francisco, Aug. 09, 2016 -- The Asia Pacific In Vitro Diagnostics (IVD) market is expected to reach USD 33.4 billion by 2024, according to a new report by Grand View Research, Inc. The Asia Pacific IVD market is anticipated to witness lucrative growth during the period 2016 to 2024. The growth of the market is attributed to an increase in the number of infectious and chronic diseases as well as technological advancements in the field of in vitro diagnostics.
Additionally, factors such as an increase in per capita income, the swiftly growing economies of India and China, increase in gross domestic product, and the rising disposable income are expected to be opportunistic for the industry growth. However, the presence of stringent regulatory policies, inadequate budget, and reimbursement issues are likely to hinder the growth of the market in the near future.
The Asia Pacific IVD market is segmented into technology, application, end-user, and region. Based on the product type, the industry is categorized into reagents, instruments, and services. The reagents market is estimated to hold the largest revenue share owing to the extensive use of reagents in diagnostics.
The molecular diagnostics segment is anticipated to be the fastest growing segment. On the basis of application, the market is categorized into infectious diseases, oncology, cardiology, nephrology, autoimmune diseases, HIV and drug testing. The large market share of this segment is attributed to the rising prevalence of infectious diseases. End-user applications include hospitals, laboratories, homecare diagnostics, and research institutes among others.
Browse full research report with TOC on “Asia Pacific In Vitro Diagnostics (IVD) Market Analysis, By Product (Reagents, Instruments, And Services), By Technology (Immunoassays, Clinical Chemistry, Hematology, Molecular Diagnosis, Microbiology And Coagulation), By Application (Infectious Diseases, Oncology, Cardiology, Nephrology, Autoimmune Diseases, HIV, Drug Testing), By End-Use (Hospitals, Laboratories, Homecare Diagnostics, Research Institutes) And Segment Forecasts To 2024” at: http://www.grandviewresearch.com/industry-analysis/asia-pacific-in-vitro-diagnostics-ivd-market
Further key findings from the study suggest:
- In terms of growth, the Chinese in vitro diagnostics industry is anticipated to witness rapid growth in the next few years. Factors attributing to the growth of this industry in China include the increasing healthcare expenditure, GDP growth, rising population base, and more favorable health insurance coverage.
- Infectious diseases segment was identified as the largest revenue generating category in the application segment and is estimated to maintain its position due to the continual rise in the number of diseases estimated for the next few years.
- The in vitro diagnostics industry comprises several local as well as global players. Some of the major players in this industry include Danaher Corporation, Affymetrix, Inc., Abbott Laboratories, Alere, Inc., Roche Diagnostics among others.
- In order to gain a major share in the industry, the companies adopted both organic as well as inorganic growth strategies. The key strategies undertaken by the companies are new product development, mergers, collaborations, partnerships, geographical expansions, and acquisitions. For instance,in October 2015, Cepheid announced the launch of its newly developed, FDA approved test ‘Xpert TV’, an in-vitro diagnostic test for the accurate identification ofTrichomoniasis in female patients.
Browse related reports by Grand View Research:
- Dental Diagnostics And Surgical Equipment Market
- Diagnostic Electrocardiography Devices Market
- Human papilloma virus Testing Market
Grand View Research has segmented the Asia Pacific in vitro diagnostics market on the basis of end-user, application, and region:
Asia Pacific In Vitro Diagnostics Product Outlook (Revenue, USD Million, 2013 - 2024)
- Reagents
- Instruments
- Services
Asia Pacific In Vitro Diagnostics Technology Outlook (Revenue, USD Million, 2013 - 2024)
- Immunoassays
- Clinical Chemistry
- Hematology
- Molecular Diagnosis
- Microbiology
- Coagulation
- Others
Asia Pacific In Vitro Diagnostics Application Outlook (Revenue, USD Million, 2013 - 2024)
- Infectious Diseases
- Diabetes
- Oncology
- Cardiology
- Nephrology
- Autoimmune Diseases
- Drug Testing
- Others
Asia Pacific In Vitro Diagnostics End-User Outlook (Revenue, USD Million, 2013 - 2024)
- Hospitals
- Laboratories
- Homecare Diagnostics
- Others
Asia Pacific In Vitro Diagnostics Regional Outlook (Revenue, USD Million, 2013 - 2024)
- India
- China
- Japan
Read Our Blogs – ni2014.org , grandviewresearch.com/blogs/healthcare
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
email: [email protected]
Web: www.grandviewresearch.com


Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
OpenAI Explores Massive Funding Round at $750 Billion Valuation
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 



